Stevanato Group and Colanar have signed an agreement for lab scale fill/finish capabilities to study container closure systems at Stevanato Group’s US TEC in Boston, MA.
Stevanato Group and Colanar have signed an agreement for lab scale fill/finish capabilities to study container closure systems at Stevanato Group’s United States Technology Excellence Center (US TEC) in Boston, MA. The agreement was announced in a July 21, 2020 press release.
Under the terms of the agreement, Stevanato Group’s US TEC will be equipped with Colanar’s fill/finish machine that can perform analytical characterization and determine critical factors impacting container closure systems, the FSM machine. It is expected that the FSM will enable scientists at the US TEC to fill glass containers with buffers, placebos, and drug products immediately and test them, providing rapid data on the impact of the filling process on the formulation and container closure system.
“The FSM machine is a key asset in our laboratory that will provide biopharma customers with an additional service for conducting stability testing on filled products,” said Abizer Harianawala, site leader at Stevanato Group TEC, in the press release. “It will ensure our new US TEC provides robust data for critical fill/finish parameters for clinical batch manufacturing, facilitating scale-up, and commercialization.”
Bernd Stroeter, president at COLANAR added, in the press release, “We are proud to partner with Stevanato Group at its US TEC complementing its offering with our proven and scalable fill/finish solution for biologics. The combination of our reliable equipment and the extensive testing methods supplied by Stevanato Group’s US TEC will support biopharma companies selecting the best-suited container and drug handling, de-risking the entire manufacturing process, and improving the time to market.”
Source: Stevanato Group
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.